ArticleClinical journal of gastroenterology2008
Development from simple steatosis to liver cirrhosis and hepatocellular carcinoma: a 27-year follow-up case.
Article in Clinical journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Inhibition of polyploidization in Pten-deficient livers reduces steatosis.Liver international : official journal of the International Association for the Study of the Liver · 2022Article
- Relationship between Liver Stiffness and Steatosis in Obesity Conditions: In Vivo and In Vitro Studies.Biomolecules · 2022Article
- Impact of qualitative endoscopic ultrasonography on fatty pancreas at a referral medical center.JGH open : an open access journal of gastroenterology and hepatology · 2022Article
- Impact of Dietary Fat on the Progression of Liver Fibrosis: Lessons from Animal and Cell Studies.International journal of molecular sciences · 2021Review
- PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice.International journal of molecular sciences · 2020Review
- Current status, problems, and perspectives of non-alcoholic fatty liver disease research.World journal of gastroenterology · 2019Review
- Article
- Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease.World journal of gastroenterology · 2018Article
- Targeting nuclear receptors for the treatment of fatty liver disease.Pharmacology & therapeutics · 2017Review
- Association between endotoxemia and histological features of nonalcoholic fatty liver disease.World journal of gastroenterology · 2017Article
- The Nutraceutic Silybin Counteracts Excess Lipid Accumulation and Ongoing Oxidative Stress in anFrontiers in nutrition · 2017Article
- PPARα protects against trans-fatty-acid-containing diet-induced steatohepatitis.The Journal of nutritional biochemistry · 2017Article
- Pancreatic fat accumulation, fibrosis, and acinar cell injury in the Zucker diabetic fatty rat fed a chronic high-fat diet.Pancreas · 2014Article
- Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy.Journal of gastroenterology · 2011Article
- Eicosapentaenoic acid improves hepatic steatosis independent of PPARα activation through inhibition of SREBP-1 maturation in mice.Biochemical pharmacology · 2010Article
- Nonalcoholic fatty liver disease in Japanese junior high school students: its prevalence and relationship to lifestyle habits.Journal of gastroenterology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is classified as nonalcoholic steatohepatitis (NASH) or simple steatosis (SS) according to histological findings. It is well recognized that NASH may develop into cirrhosis and hepatocellular carcinoma (HCC), both with unfavorable prognoses. Although the outlook of SS is reported to be better than that of NASH, the long-term prognosis of SS remains unclear. Here, we report the case of a patient who was diagnosed as having SS by a first liver biopsy, and later developed into cirrhosis and HCC over a period of 27 years. In 1980, a 42-year-old Japanese man was admitted because of abnormal liver function tests. He had no history of alcohol intake and was negative for hepatitis virus markers and autoantibodies. A liver biopsy specimen showed macrovesicular steatosis without ballooned hepatocytes, Mallory hyaline, lobular inflammation, or perisinusoidal/perivenular fibrosis, confirming the diagnosis of SS. The patient's serum aminotransferase levels did not normalize despite repeated dietary instruction, and in 2001, liver histology demonstrated cirrhosis with mild steatosis and hepatocyte ballooning, leading to the diagnosis of NASH-related cirrhosis. HCC appeared in 2007. Overall, this patient progressed to cirrhosis and HCC in 20 and 27 years, respectively, following initial diagnosis. Platelet counts and degree of steatosis, as assessed by periodic ultrasonography, were seen to gradually reduce with progression of fibrosis. This case demonstrates that even a diagnosis of SS does not guarantee non-progression to cirrhosis and HCC, and careful follow-up is needed not only in patients with NASH, but also in those with SS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.